Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech Activase

Executive Summary

Results of ASSET (Anglo-Scandinavian Study of Early Thrombolysis) mortality study published in the Sept. 3 issue of The Lancet show overall one month fatality rates with TPA at 7.2% versus 9.8% with placebo in the 5,009 patient study, representing a relative reduction of 26% (95% confidence interval 11-39%). "The 26% reduction of fatality rate is similar to that seen in the ISAM, GISSI, and ISIS-2 trials for streptokinase (12%, 18% and 21%, respectively, or 16%, 20%, and an estimated 27% for patients treated within 6 hours of onset)," the investigators observed. "The effect on 6 month mortality in ASSET will be described later but, by analogy with the late results of GISSI, it seems likely that the difference between groups observed at one month will remain unchanged".

You may also be interested in...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?

“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts